Press Release Details

Cerus Corporation Files Shelf Registration Statement

August, 10 2001

Business Editors/Health & Medical Writers

CONCORD, Calif.--(BUSINESS WIRE)--Aug. 10, 2001

Cerus Corporation (Nasdaq:CERS) today announced that it has filed a Form S-3 shelf registration statement with the Securities and Exchange Commission for the sale of up to an aggregate of $300 million of common stock and debt securities.

A registration statement relating to these securities has been filed with the Securities and Exchange Commission but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This news release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.

About Cerus

Cerus Corporation is developing medical systems and therapeutics based on its proprietary Helinx technology for controlling biological replication. Cerus' most advanced programs are focused on systems to enhance the safety of blood products used for transfusion. These INTERCEPT Blood Systems, based on the company's Helinx technology, are designed to inactivate viruses, bacteria, other pathogens and white blood cells. The Concord, California-based company also is pursuing therapeutic applications of Helinx technology to treat and prevent serious diseases.

Note to Editors: Helinx is a trademark of Cerus Corporation INTERCEPT Blood System, INTERCEPT Platelet System, INTERCEPT Plasma System and INTERCEPT Red Blood Cell System are trademarks of Baxter International, Inc. (NYSE: BAX).

Statements in this press release concerning potential financing and product development are forward-looking statements that involve risks and uncertainties. Actual results could differ materially. Factors that could cause or contribute to such differences are discussed in Cerus' quarterly report on Form 10-Q for the period ended June 30, 2001.

    Global Headquarters

  • 1220 Concord Avenue
  • Concord, CA US 94520
  • +1 925.288.6000

    European Headquarters

  • Stationsstraat 79-D
  • 3811 MH Amersfoort, Netherlands
  • +31 (0) 33 49 60 600